Engineering Elizabethkingia meningoseptica sp. F2 for Vitamin K2 production guided by genome analysis.

Abstract Background The species in family Elizabethkingia meningoseptica are interesting strain for investigating Vitamin K2 metabolic analysis. However, their genomic sequence, metabolic pathway, potential abilities, and evolutionary status are still unknown. Results This study therefore aimed to perform a genome sequencing of Elizabethkingia meningoseptica sp. F2 and further accomplished comparative analysis with other Vitamin K2 strains reveals overall identifying its unique/shared metabolic genes across genomes. The 3,874,794–base pair sequence of Elizabethkingia meningoseptica sp. F2 is presented. Of 3,539 genes annotation was applied. Results of synteny block demonstrated Elizabethkingia meningoseptica sp. F2 shares high levels of synteny with Elizabethkingia meningoseptica ATCC 13253 and Elizabethkingia meningoseptica NBRC 12535. Identification of Vitamin K2 metabolic pathway in Elizabethkingia meningoseptica sp. F2 were also accomplished. In addition, Elizabethkingia meningoseptica sp. F2 was resistant to gentamicin, streptomycin, ampicillin and caramycin, consistent with the presence of multiple genes encoding diverse multidrug efflux pump protein in the genome. Furthermore, By co-overexpression experiments of MenA and MenG, we showed that Vitamin K2 content was enhanced by 37% compared with control strain. Conclusions The genome analysis of Elizabethkingia meningoseptica sp. F2 in conjunction with the comparative metabolic pathways analysis among the E.coli, Bacillus subtilis and Streptomyces provided a useful information on the Vitamin K2 biosynthetic pathway and other related pathways at systems level.